Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Petros Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, NY / ACCESS NEWSWIRE / JUNE 25, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER THE COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY ANNOUNCES THE STRATEGIC DECONSOLIDATION OF ITS WHOLLY OWNED SUBSIDIARY, METUCHEN PHARMACEUTICALS LLC ("METUCHEN"), INCLUDING ITS WHOLLY OWNED SUBSIDIARIES, TIMM MEDICAL TECHNOLOGIES, INC. AND POS-T-VAC, LLC, FROM ITS CONSOLIDATED BALANCE SHEET, EFFECTIVE BEGINNING IN ITS QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDING JUNE 30, 2025. THIS MOVE IS EXPECTED TO SIGNIFICANTLY IMPROVE PETROS' FINANCIAL POSITION, INCREASING STOCKHOLDERS' EQUITY AND MATERIALLY REDUCING CONSOLIDATED DEBT.

PETROS PHARMACEUTICALS ANNOUNCES DECONSOLIDATION OF METUCHEN PHARMACEUTICALS SUBSIDIARY, STRENGTHENING ITS BALANCE SHEET AND IMPROVING THE COMPANY'S EQUITY POSITION

THE COMPANY INTENDS TO APPEAL THE DELISTING DETERMINATION NEW YORK, NY / ACCESS NEWSWIRE / MAY 21, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER THE COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY ANNOUNCES THAT IT HAS RECEIVED A STAFF DETERMINATION LETTER FROM THE NASDAQ STOCK MARKET, LLC ("NASDAQ"), INFORMING THE COMPANY THAT NASDAQ DETERMINED TO SUSPEND TRADING AND DELIST THE COMPANY'S COMMON STOCK FROM NASDAQ. AT THE OPEN OF TRADING ON THURSDAY, MAY 22, 2025, PETROS' SECURITIES WILL BE SUSPENDED ON NASDAQ AND ARE EXPECTED TO BEGIN TRADING ON THE OTC MARKETS UNDER THE TICKER "PTPI".

PETROS PHARMACEUTICALS ANNOUNCES TRANSITION FROM NASDAQ TO OTC MARKETS

WITH MORE THAN $10M IN CASH, AND A SIGNIFICANTLY REDUCED BURN RATE, THE COMPANY IS POSITIONED TO FULLY FUND THE DEVELOPMENT OF ITS TECHNOLOGY PLATFORM. NEW YORK, NY / ACCESS NEWSWIRE / MAY 20, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER THE COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY ANNOUNCES ITS PARTNERSHIP WITH INNOLITICS, A LEADING DEVELOPER IN THE SOFTWARE-AS-A-MEDICAL DEVICE SPACE.

PETROS PHARMACEUTICALS PARTNERS WITH INNOLITICS, A LEADING SOFTWARE-AS-A-MEDICAL-DEVICE DEVELOPER

COMPANY CONTINUES TO INNOVATE AND DEVELOP ITS SAAS-BASED PLATFORM TO FACILITATE RX-TO-OTC SWITCH IN LINE WITH RECENT PRESIDENT TRUMP EXECUTIVE ORDER NEW YORK, NY / ACCESS NEWSWIRE / MAY 6, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER THE COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY ANNOUNCES IT HAS IMPLEMENTED MULTIPLE ENHANCEMENTS TO ITS DEVELOPING AI PLATFORM, WHICH IS EXPECTED TO IMPROVE PROCESSING AND FRAUD DETECTION AND PROVIDE A BETTER OVERALL EXPERIENCE. THE AI PLATFORM IS EXPECTED TO BE A KEY COMPONENT OF THE COMPANY'S RECENTLY ANNOUNCED SAAS-BASED TECHNOLOGY, INTEGRATING PETROS' SOFTWARE AS A MEDICAL DEVICE ("SAMD") PROPRIETARY SOLUTION, WHICH IS BEING DESIGNED TO HELP FACILITATE EXPANDING ACCESS FOR ESTABLISHED PRESCRIPTION DRUGS BY BRINGING THEM OVER THE COUNTER.

PETROS PHARMACEUTICALS STRENGTHENS PARTNERSHIP WITH MARKET LEADING BIG DATA PROVIDER IMPLEMENTING KEY ENHANCEMENTS TO ITS AI PLATFORM

LICENSABLE PLATFORM INTENDED TO FACILITATE INDUSTRY COMPLIANCE WITH PRESIDENT TRUMP'S RECENT EXECUTIVE ORDER TO EXPAND ACCESS TO MEDICINES THROUGH OTC APPROVALS UNDER HIS MAKE AMERICA HEALTHY AGAIN (MAHA) INITIATIVE NEW YORK, NY / ACCESS NEWSWIRE / MAY 1, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER THE COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY ANNOUNCES A CONCERTED EFFORT TOWARD EVOLVING INTO A SMART HEALTHCARE TECHNOLOGY COMPANY THROUGH THE DEVELOPMENT OF A SAAS PLATFORM DESIGNED TO COMPLEMENT ITS PROPRIETARY WEB APPLICATION (ALSO KNOWN AS A SOFTWARE AS A MEDICAL DEVICE, OR SAMD). THE LICENSABLE PLATFORM IS BEING DESIGNED TO INTEGRATE KEY CLOUD-BASED COMPONENTS, INCLUDING AI, ELECTRONIC HEALTH RECORDS, CYBERSECURITY AND OTHERS TO PROVIDE POTENTIAL PRESCRIPTION TREATMENTS AND PHARMACEUTICAL SPONSORS WITH A COMMERCIALLY VIABLE AND ENTERPRISE SCALED PLATFORM.

PETROS PHARMACEUTICALS DEVELOPING FIRST-IN-INDUSTRY SAAS PLATFORM UTILIZING AI AND ELECTRONIC HEALTH RECORDS INTENDED TO FACILITATE RX-OTC SWITCHES

COMPANY'S AI AND BIG DATA TECHNOLOGY POSITIONED TO DRIVE STRONG INDUSTRY COLLABORATION COMPANY ALSO ANNOUNCES CERTAIN CORPORATE ACTIONS NEW YORK, NY / ACCESS NEWSWIRE / APRIL 29, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER THE COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY HIGHLIGHTS PRESIDENT TRUMP'S APRIL 15, 2025 EXECUTIVE ORDER, TITLED, "LOWERING DRUG PRICES BY ONCE AGAIN PUTTING AMERICANS FIRST" (THE "EXECUTIVE ORDER"), AS A DEMONSTRATION THAT THE COMPANY'S RECENT STRATEGIC SHIFT IS WELL TIMED TO THE CURRENT REGULATORY CLIMATE, WHERE PETROS BELIEVES IT HAS ALREADY MADE SIGNIFICANT ADVANCEMENTS. PETROS' DEVELOPMENT OF ITS BIG DATA AND AI-DRIVEN SOFTWARE-AS-A-MEDICAL DEVICE PLATFORM PRESENTS AN IMPORTANT OPPORTUNITY FOR THE PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO THE LOWERING OF DRUG PRICES WHILE UTILIZING AN EMERGING, YET PROVEN, METHODOLOGY THAT CONFORMS WITH FDA GUIDANCE TO ENSURE A SAFE TRANSITION FROM RX TO OTC.

PETROS PROPRIETARY TECHNOLOGY PLATFORM ALIGNS WITH APRIL 15, 2025 PRESIDENT TRUMP EXECUTIVE ORDER ADVANCING RX-TO-OTC RECLASSIFICATION REFORMS

COMPANY TO INTEGRATE INDUSTRY LEADING BIG DATA TECHNOLOGY SOLUTIONS INTO ITS AI-DRIVEN PLATFORM TO EXPAND CAPABILITIES IN IDENTIFYING ELIGIBLE PATIENTS TO RECEIVE FORMERLY RX MEDICATIONS OVER THE COUNTER NEW YORK, NY / ACCESS NEWSWIRE / MARCH 20, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER-THE-COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY ANNOUNCES A COLLABORATION WITH RENOWNED BIG DATA AND ANALYTICS LEADER TO ENHANCE THE DEVELOPMENT OF ITS PROPRIETARY TECHNOLOGY SOLUTIONS DESIGNED TO FACILITATE RX-TO-OTC SWITCHES FOR PHARMACEUTICAL PRODUCTS. THE COLLABORATION WILL INCORPORATE AN AUTOMATED CREDENTIALING SOLUTION TO HELP IMPROVE THE COMPANY'S IDENTITY VERIFICATION SYSTEM, WHICH ALSO ENCOMPASSES AN AI COMPONENT.

PETROS PHARMACEUTICALS TO PARTNER WITH RENOWNED BIG DATA PROVIDER TO ENABLE RX-TO-OTC SWITCH ACROSS MULTIPLE INDICATIONS

PROPRIETARY TECHNOLOGY UTILIZING AI AND BIG DATA INTEGRATIONS TO ENABLE RX TO OTC SWITCH CANDIDATES ACROSS MULTIPLE INDICATIONS NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 25, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER-THE-COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, ANNOUNCES TOP-LINE RESULTS OF ITS EXPANDED APPLICATION COMPREHENSION ("APP COMP") STUDY, WHICH DETERMINES CONSUMER COMPREHENSION OF ITS UNIQUE MESSAGING WITHIN ITS PROPRIETARY TECHNOLOGY. IN THE STUDY, THE COMPANY'S TECHNOLOGY FACILITATED CONSUMER'S UNDERSTANDING OF DESIGNATED CRITICAL OBJECTIVES (WITH A SUCCESS THRESHOLD OF 90% OR 85% BASED ON CLINICAL SIGNIFICANCE OF THE OBJECTIVE).

PETROS PHARMACEUTICALS' PROPRIETARY TECHNOLOGY DEMONSTRATES POSITIVE DATA IN PIVOTAL STUDY

NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 18, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER-THE-COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY ANNOUNCES THE PRICING OF A PUBLIC OFFERING OF APPROXIMATELY 40,000,000 SHARES OF THE COMPANY'S COMMON STOCK ("COMMON STOCK"), PAR VALUE $0.0001 PER SHARE (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), WITH EACH SHARE OF COMMON STOCK (OR PRE-FUNDED WARRANT) ACCOMPANIED BY (I) A SERIES A WARRANT TO PURCHASE 0.25 SHARE OF COMMON STOCK AT AN EXERCISE PRICE OF $0.48 PER 0.25 SHARE ("SERIES A WARRANT") AND (II) A SERIES B WARRANT TO PURCHASE ONE (1) SHARE OF COMMON STOCK AT AN EXERCISE PRICE OF $0.48 PER SHARE ("SERIES B WARRANT"). THE COMBINED PUBLIC OFFERING PRICE OF EACH SHARE OF COMMON STOCK TOGETHER WITH THE ACCOMPANYING SERIES A WARRANT AND SERIES B WARRANT IS $0.24, AND THE COMBINED PUBLIC OFFERING PRICE OF EACH PRE-FUNDED WARRANT TOGETHER WITH THE ACCOMPANYING SERIES A WARRANT AND SERIES B WARRANT IS $0.2399, WHICH REPRESENTS THE PER SHARE OFFERING PRICE FOR THE COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

PETROS PHARMACEUTICALS ANNOUNCES PRICING OF $9.6 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

PROPRIETARY TECHNOLOGY DEVELOPING QUANTUM COMPUTING AND APPLYING AI TO BETTER ENABLE RX TO OTC SWITCH CANDIDATES ACROSS MULTIPLE INDICATIONS NEW YORK, NY / ACCESSWIRE / JANUARY 7, 2025 / PETROS PHARMACEUTICALS, INC. (NASDAQ:PTPI) ("PETROS" OR THE "COMPANY"), A COMPANY FOCUSED ON EXPANDING CONSUMER ACCESS TO MEDICATION THROUGH OVER-THE-COUNTER ("OTC") DRUG DEVELOPMENT PROGRAMS, TODAY ANNOUNCES ITS CONDUCIVE POSITION IN CONNECTION WITH THE RECENTLY ISSUED FINAL RULE, "NONPRESCRIPTION DRUG PRODUCT WITH AN ADDITIONAL CONDITION FOR NONPRESCRIPTION USE" ("ACNU") BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (THE "FDA") FOR COMPANIES SEEKING RX-TO-OTC SWITCH FOR PHARMACEUTICAL PRODUCTS. THE COMPANY'S RECENTLY ANNOUNCED SHIFT IN ITS PRIMARY BUSINESS STRATEGY WAS INITIALLY DEVELOPED UNDER GUIDANCE OF EARLIER ITERATIONS OF THE RULE, AND THE COMPANY BELIEVES THE FINAL RULE WILL HELP FACILITATE THE DEVELOPMENT OF ITS SOFTWARE AS A MEDICAL DEVICE (SAMD) CONCEPT, WHICH IS DESIGNED TO SERVE THE EMERGING SELF-CARE MARKET.

Petros Pharmaceuticals, Inc.

PTPI

Price

Financial Reports

No items found.

Press Releases

Petros Pharmaceuticals, Inc.

PTPI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PTPI